Ezetimibe Is an Inhibitor of Tumor Angiogenesis
- 31 March 2009
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 174 (3), 1017-1026
- https://doi.org/10.2353/ajpath.2009.080551
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Plasma Membrane Cholesterol Content Affects Nitric Oxide Diffusion Dynamics and SignalingOnline Journal of Public Health Informatics, 2008
- Dietary patterns and risk of prostate cancer in Ontario, CanadaInternational Journal of Cancer, 2005
- Caveolae and Caveolins in the Cardiovascular SystemCirculation Research, 2004
- Effectiveness of ezetimibe in clinical practiceThe American Journal of Cardiology, 2004
- Cholesterol and prostate cancerJournal of Cellular Biochemistry, 2003
- CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolismJCI Insight, 2001
- Caveolin‐Enriched Membrane Signaling Complexes in Human and Murine OsteoblastsJournal of Bone and Mineral Research, 2000
- The application of an antiangiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenograftsCancer Gene Therapy, 2000
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996